KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $22.4 million.

  • Arbutus Biopharma's Cash & Equivalents fell 2963.64% to $22.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.4 million, marking a year-over-year decrease of 2963.64%. This contributed to the annual value of $36.3 million for FY2024, which is 3821.57% up from last year.
  • As of Q3 2025, Arbutus Biopharma's Cash & Equivalents stood at $22.4 million, which was down 2963.64% from $37.4 million recorded in Q2 2025.
  • Over the past 5 years, Arbutus Biopharma's Cash & Equivalents peaked at $109.3 million during Q4 2021, and registered a low of $17.5 million during Q3 2023.
  • For the 5-year period, Arbutus Biopharma's Cash & Equivalents averaged around $45.4 million, with its median value being $37.1 million (2025).
  • In the last 5 years, Arbutus Biopharma's Cash & Equivalents skyrocketed by 20065.49% in 2021 and then tumbled by 7183.8% in 2022.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Cash & Equivalents stood at $109.3 million in 2021, then plummeted by 71.84% to $30.8 million in 2022, then dropped by 14.59% to $26.3 million in 2023, then skyrocketed by 38.22% to $36.3 million in 2024, then plummeted by 38.32% to $22.4 million in 2025.
  • Its Cash & Equivalents stands at $22.4 million for Q3 2025, versus $37.4 million for Q2 2025 and $37.1 million for Q1 2025.